The abstract is read at the publisher; the summary is JClub's.
DNA damage response and biomarker-defined vulnerabilities in recurrent or treatment-resistant gynecological malignancies show encouraging clinical activity, including targets like WEE1, PKMYT1, WRN, and CCNE1 amplification.
- Why it matters: Recurrent and treatment-resistant disease drives high cancer morbidity and mortality, and conventional chemotherapy and early targeted agents are often insufficient.
- What they did: The review synthesizes recent early-phase development of biomarker-driven therapies, including DNA damage response inhibitors, CCNE1-amplification–linked strategies, and actionable alterations such as TP53 Y220C.
- The result: It summarizes how antibody-drug conjugates and next-generation immunotherapies (e.g., bispecific antibodies, T-cell engagers, engineered T-cell receptor therapies, and CAR-T cells) are evolving, while tumor heterogeneity, biomarker complexity, and acquired resistance shape future biomarker-driven sequencing.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.